Long-term xanthine therapy of asthma. Enprofylline and theophylline compared. International Enprofylline Study Group.

Background: Enprofylline is a new xanthine derivative that shares theophylline's bronchodilator properties but is free of theophylline's adenosine receptor antagonist activity. We compared the long-term efficacy and tolerability of enprofylline and theophylline given over a 1-year period to adults with asthma.

Methods: Patients were recruited from 18 centers and 4 countries to participate in a 1-month double-blind comparison of enprofylline or theophylline in the treatment of asthma and were subsequently maintained on a regimen with the assigned medication for a further 11 months.

Transfer of enprofylline into breast milk.

Enprofylline concentrations were measured on 3 consecutive days in milk and plasma from six nursing mothers who were treated twice daily with 150-mg enprofylline slow-release tablets. The mean plasma concentration was 0.89 mg/L and the mean milk concentration was 0.

Efficacy of enprofylline, a new bronchodilating xanthine, in acute asthma.

Five different doses of enprofylline, a 3-propylxanthine, were compared with a standard dose of theophylline in 135 episodes of acute asthma in a double-blind study. The drugs were administered intravenously during ten minutes. Enprofylline induced dose-related bronchodilation and the 2.

A comparison of the clinical and bronchodilating effects of plain and slow-release tablets of terbutaline at steady state.

The clinical efficacy, the bronchodilating effect and the side effects of two oral forms of terbutaline were compared in a double-blind, cross-over study involving ten patients with chronic reversible airways obstruction. The administration of plain-tablets, containing 2.5 mg terbutaline sulphate, three times daily at 6 h intervals was compared to the administration of slow-release (SR) tablets, containing 5 mg terbutaline sulphate, every 12 h.

Acute asthma--plasma levels and effect of terbutaline i.v. injection.

The effects of two different doses (4 and 8 micrograms/kg) of terbutaline i.v. injection were recorded in 64 episodes of acute asthma (heart rate greater than 100 beats/min, peak expiratory flow (PEF) less than 50% of the predicted normal value).